These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 30344487)

  • 1. The Emerging Role of Energy Metabolism and Neuroprotective Strategies in Parkinson's Disease.
    Błaszczyk JW
    Front Aging Neurosci; 2018; 10():301. PubMed ID: 30344487
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting energy metabolism via the mitochondrial pyruvate carrier as a novel approach to attenuate neurodegeneration.
    Quansah E; Peelaerts W; Langston JW; Simon DK; Colca J; Brundin P
    Mol Neurodegener; 2018 May; 13(1):28. PubMed ID: 29793507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Parkinson's disease : what's on the horizon?
    Wu SS; Frucht SJ
    CNS Drugs; 2005; 19(9):723-43. PubMed ID: 16142989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progresses in both basic research and clinical trials of NAD+ in Parkinson's disease.
    Pérez MJ; Baden P; Deleidi M
    Mech Ageing Dev; 2021 Jul; 197():111499. PubMed ID: 33989633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ghrelin is neuroprotective in Parkinson's disease: molecular mechanisms of metabolic neuroprotection.
    Bayliss JA; Andrews ZB
    Ther Adv Endocrinol Metab; 2013 Feb; 4(1):25-36. PubMed ID: 23515333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging neuroprotective effect of metformin in Parkinson's disease: A molecular crosstalk.
    Paudel YN; Angelopoulou E; Piperi C; Shaikh MF; Othman I
    Pharmacol Res; 2020 Feb; 152():104593. PubMed ID: 31843673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson's disease: neuroprotective strategies.
    Grünblatt E; Mandel S; Youdim MB
    J Neurol; 2000 Apr; 247 Suppl 2():II95-102. PubMed ID: 10991672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leads for the development of neuroprotective treatment in Parkinson's disease and brain imaging methods for estimating treatment efficacy.
    Stoof JC; Winogrodzka A; van Muiswinkel FL; Wolters EC; Voorn P; Groenewegen HJ; Booij J; Drukarch B
    Eur J Pharmacol; 1999 Jun; 375(1-3):75-86. PubMed ID: 10443566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotective effects of insulin-like growth factor-2 in 6-hydroxydopamine-induced cellular and mouse models of Parkinson's disease.
    Zhang HY; Jiang YC; Li JR; Yan JN; Wang XJ; Shen JB; Ke KF; Gu XS
    Neural Regen Res; 2023 May; 18(5):1099-1106. PubMed ID: 36254999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tetracycline repurposing in neurodegeneration: focus on Parkinson's disease.
    Bortolanza M; Nascimento GC; Socias SB; Ploper D; Chehín RN; Raisman-Vozari R; Del-Bel E
    J Neural Transm (Vienna); 2018 Oct; 125(10):1403-1415. PubMed ID: 30109452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Is there an effective neuroprotective treatment of Parkinson's disease? (therapeutic possibilities against the background of etiopathogenetic concepts].
    Sławek J
    Neurol Neurochir Pol; 2000; 34(4):733-42. PubMed ID: 11105305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parkinson's disease, insulin resistance and novel agents of neuroprotection.
    Aviles-Olmos I; Limousin P; Lees A; Foltynie T
    Brain; 2013 Feb; 136(Pt 2):374-84. PubMed ID: 22344583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GIP has neuroprotective effects in Alzheimer and Parkinson's disease models.
    Zhang ZQ; Hölscher C
    Peptides; 2020 Mar; 125():170184. PubMed ID: 31705913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The neuroprotective effects of intermittent fasting on brain aging and neurodegenerative diseases via regulating mitochondrial function.
    Zhao Y; Jia M; Chen W; Liu Z
    Free Radic Biol Med; 2022 Mar; 182():206-218. PubMed ID: 35218914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re-routing Metabolism by the Mitochondrial Pyruvate Carrier Inhibitor MSDC-0160 Attenuates Neurodegeneration in a Rat Model of Parkinson's Disease.
    Mallet D; Goutaudier R; Barbier EL; Carnicella S; Colca JR; Fauvelle F; Boulet S
    Mol Neurobiol; 2022 Oct; 59(10):6170-6182. PubMed ID: 35895232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotective strategies in Parkinson's disease using the models of 6-hydroxydopamine and MPTP.
    Grünblatt E; Mandel S; Youdim MB
    Ann N Y Acad Sci; 2000; 899():262-73. PubMed ID: 10863545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases.
    Alexi T; Borlongan CV; Faull RL; Williams CE; Clark RG; Gluckman PD; Hughes PE
    Prog Neurobiol; 2000 Apr; 60(5):409-70. PubMed ID: 10697073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkinson's disease as a result of aging.
    Rodriguez M; Rodriguez-Sabate C; Morales I; Sanchez A; Sabate M
    Aging Cell; 2015 Jun; 14(3):293-308. PubMed ID: 25677794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parkinson's Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy?
    Gundersen V
    Front Neurosci; 2020; 14():580311. PubMed ID: 33716638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher serum levels of pro-hepcidin in patients with Parkinson's disease treated with deep brain stimulation.
    Kwiatek-Majkusiak J; Geremek M; Koziorowski D; Tomasiuk R; Szlufik S; Friedman A
    Neurosci Lett; 2018 Sep; 684():205-209. PubMed ID: 29928951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.